Arika Carmel: Enforcement, litigation, and the trust discount on the equity

The main article already showed that Arika Carmel improved operations in 2025 without rebuilding a real financial cushion. This follow-up isolates a different layer, one that is less visible in the income statement and more damaging to the equity story: trust. This is no longer only a question of how much one sanction costs. It is a question of how much weight the market can place on management disclosure, governance, and the company’s ability to close one regulatory chapter without opening another.

That is why this topic deserves its own continuation. If an investor looks only at the 2025 profit-and-loss statement, the issue can seem largely behind the company. In practice, 2025 and early 2026 deepened the story: a full administrative enforcement decision, an equal-size conditional sanction, an external examiner for one year, an administrative petition, a second administrative review around errors in the 2021 and 2022 accounts, and a wider litigation web that prevents a clean reset.

• The damage is no longer sitting mainly in the income statement. The NIS 1.5 million provision was recorded in the 2024 accounts, so 2025 does not absorb the same accounting hit again.
• But 2025 does absorb the institutional escalation of the case. In April 2025 the enforcement decision was issued, and it came not only with a fine but also with a conditional sanction and an external examiner reviewing the internal compliance structure.
• At the same time, a second thread stayed open. Alongside the petition against the enforcement decision, a separate administrative review around the 2021 and 2022 restatements remained unresolved, while the derivative track, the former CEO’s suit, and the class-action process kept the same governance layer alive.

Why 2025 looks cleaner than it really is

The most important detail here is also the easiest to miss. The 2025 “other expenses” line does not carry the NIS 1.5 million sanction again. That is not because the issue disappeared, but because the company had already recognized it a year earlier. The April 2025 enforcement decision explicitly states that the company had already provided NIS 1.5 million in the 2024 financial statements, and the “other expenses” table shows that the amount sits in 2024 rather than in 2025.

That is accounting-correct, but analytically misleading if one stops there. In 2025, “other expenses” totaled only NIS 795 thousand, made up of NIS 753 thousand of prior-years items and NIS 42 thousand of fixed-asset disposal loss. Anyone searching for the cost of the enforcement story only in the current-year expense line will get an answer that is far too soft. Accounting closed the amount. The market has not closed the event.

The chart below does not compare legal probabilities. It compares the scales the reader sees in front of them: what has already been recognized, how much cash and securities the company had near the statement-signing date, and the size of another still-open claim elsewhere in the filings.

The message is sharp. NIS 1.5 million is not a trivial number for a company that had only about NIS 3.9 million of cash and securities near the signing date. But even that is still not the heart of the story. The heart is that the sanction already recognized in accounting did not buy certainty. It merely marked the point at which the market had to start asking whether this was a historic disclosure failure that can be ring-fenced, or a broader issue of controls, supervision, and credibility.

The sanction is no longer just a fine

The Securities Authority process began as an administrative review in February 2024 around the adequacy of disclosure on the absence of CE approval for some of the company’s products. In May 2024 the file was transferred to enforcement. By August 2024, the company had already received notice of a full administrative enforcement proceeding against the company, the controlling shareholder, and two former CEOs, over alleged untimely disclosure and misleading statements about what was required to market products in Europe and about the fact that some products lacked medical-device approval in the European Union. According to the administrative pleading, the issue covered the period from the July 2021 IPO until the first public disclosure in June 2023.

In April 2025 the matter moved from review to decision. The enforcement panel attributed the violations to the company and imposed a NIS 1.5 million monetary sanction, payable in 20 installments starting 60 days after the decision. But the story did not stop with cash. The company was also given an equal-size conditional sanction, and an external examiner was appointed for one year to review the internal enforcement program, with an emphasis on disclosure procedures, information flow, and response to regulatory risk.

That is exactly where the issue stops being one-off. A one-time fine can be absorbed. An external examiner reviewing the disclosure pipeline and the compliance architecture means the Authority is not treating this only as a past event. It is also raising a question about the system itself. For the equity market, that is a material difference, because it shifts the discussion from “what happened” to “how much confidence can be placed in what will be disclosed next.”

It is important, however, to hold the company’s side as well. The company denied the allegations, argued that it had acted in good faith and professionally, and said that it was the one that had proactively approached the Authority, investors, and the Ministry of Health to surface the issue. It also argued that the information it received from the relevant parties was that all the products had the required CE approvals. That is the core of the counter-thesis, and it matters because it leaves open the possibility that the administrative petition will narrow the significance of the decision.

But as of the report date, that possibility remained unresolved. In June 2025 the company filed an administrative petition with the Tel Aviv District Court against the finding of violations, and alternatively against the size of the sanction and the conditional sanction. In December 2025 the Authority filed its response. By February 2026 two hearings had already taken place, with another expected in April 2026. So 2025 did not end with closure. It ended with a live process rolling into 2026.

The web of proceedings matters more than the headline amount

If one focuses only on gross numbers, the eye is naturally pulled to the class-action headline of roughly NIS 115 million. But that is not the right read at the report date. By the end of March 2026, the certification request had already been dismissed on threshold grounds. Even before that, in June 2025, the court had rejected most of the amendment request and did not allow the process to expand into alleged material errors in the financial statements, the UK sales method, or marketing in Europe without appropriate CE approvals. In other words, the largest nominal headline had already weakened substantially before it fell procedurally.

That makes the analytical point more interesting than the number itself. The immediate risk is no longer a NIS 115 million class action. The real risk is that the company still cannot draw a clean line between one enforcement event and a broader governance overhang. That is what shows up in the network of proceedings still open even after the class-action track weakened.

That table explains why the “fine” is only the entry point. Even when one legal headline weakens, a wider web of proceedings, reviews, and mediation continues to bring the same issue back to the center of the company read. This does not necessarily mean all the allegations will be upheld. It does mean the market is unlikely to restore a full trust premium while the same questions keep surfacing through several channels at once.

There is also a second thread that is not only about CE. In June 2025 the company itself reported to the Authority on an investigative audit report concerning errors discovered in the 2021 and 2022 financial statements, errors that forced republication and restatement of those accounts. The Authority decided to conduct an administrative review on that matter too, and to the company’s knowledge it was still unresolved as of the report date. This may be the single most important item for the continuing trust discount, because it means that even if the CE case is narrowed, the credibility issue around prior-year accounting is still not closed.

Why this sits on the equity layer

At this point the regulatory story has to be connected to the financial position, rather than left as a footnote inside “risks.” Both the board report and the auditor’s report point to the same reality: a NIS 5.191 million operating loss in 2025, a NIS 5.853 million annual loss, accumulated losses of NIS 84.399 million, and only about NIS 3.9 million of cash and securities near the statement-signing date. At the same time, the ability to meet obligations in the foreseeable future still depends on management plans, an efficiency program, deferred payments, inventory that can be sold, and agreements with customers and distributors.

In a company in that position, trust is not cosmetic. It is part of the equity base. It affects how investors read every financing event, how much credit the market gives to management forecasts, and how willing the market is to underwrite future commercialization and regulatory milestones. When the company still has to prove operating improvement, regulatory progress, and funding stability at the same time, any additional noise in enforcement and governance increases the discount the market is likely to apply to the shares.

That is also why the real damage is larger than the provision. NIS 1.5 million is a known accounting number. But a conditional sanction, an external examiner, an open petition, and an additional review around prior-year accounts tell the market that it is still pricing the probability of the next credibility problem, not only the cost of the previous one. For a small listed medtech and distribution company that still depends on investor confidence and access to capital, that is a classic trust discount on the equity.

What has to happen for the discount to close

For this layer to start closing, it is not enough for the company to post one more decent quarter of sales or gross margin. Something has to improve at the system level.

• The administrative petition has to become clearer. Not necessarily through a complete win, but at least in a way that gives the market a cleaner frame around the sanction, the conditional sanction, and the external examiner.
• The second administrative review around the 2021 and 2022 errors has to end without producing a new wave of findings. As long as that thread is also open, it is hard to talk about a real trust reset.
• The company has to go through a period without another disclosure fracture, precisely while it is trying to advance commercialization and regulatory work. In a medical-device and distribution story, proving reporting discipline matters almost as much as proving the next commercial step.

Bottom line

The superficial read says the sanction has already been absorbed, because the provision was booked back in 2024 and the 2025 income statement does not take the same hit again. The correct read is much more demanding. 2025 is the year in which the enforcement episode turned from an amount in the accounts into a system-level overhang: an open petition, an external examiner, an additional review on prior-year accounts, and a wider litigation network that keeps governance and disclosure at the center of the thesis.

That is why the trust discount on Arika Carmel cannot be measured only by NIS 1.5 million. It has to be measured by whether the market can start believing that the problem has been defined, priced, and contained, or whether this is still a company that has to prove not only sales and cash flow, but also that the system generating disclosure and regulatory compliance is stable enough to carry the story forward.